Atyr PHARMA INC (NASDAQ:ATYR – Get Free Report) was the recipient of a significant decrease in short interest during the month of October. As of October 15th, there was short interest totalling 1,070,000 shares, a decrease of 21.3% from the September 30th total of 1,360,000 shares. Approximately 1.5% of the shares of the company are short sold. Based on an average daily trading volume, of 684,000 shares, the days-to-cover ratio is presently 1.6 days.
Atyr PHARMA Stock Up 7.2 %
Shares of Atyr PHARMA stock traded up $0.24 on Tuesday, reaching $3.56. The company’s stock had a trading volume of 503,636 shares, compared to its average volume of 557,523. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.63 and a quick ratio of 7.63. The firm has a market capitalization of $245.68 million, a P/E ratio of -4.04 and a beta of 1.21. The business has a 50-day simple moving average of $2.11. Atyr PHARMA has a 52-week low of $1.08 and a 52-week high of $3.68.
Atyr PHARMA (NASDAQ:ATYR – Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.01. Sell-side analysts forecast that Atyr PHARMA will post -0.91 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Read Our Latest Report on ATYR
Atyr PHARMA Company Profile
aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.
Read More
- Five stocks we like better than Atyr PHARMA
- Why Are These Companies Considered Blue Chips?
- QuantumScape: Solid State EV Batteries Nearing Commercialization
- Health Care Stocks Explained: Why You Might Want to Invest
- MicroStrategy: Is This Bitcoin-Powered Stock a Buy or a Gamble?
- Canadian Penny Stocks: Can They Make You Rich?
- 3 Stocks Reporting Kitchen Sink Quarters to Usher in a Turnaround
Receive News & Ratings for Atyr PHARMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atyr PHARMA and related companies with MarketBeat.com's FREE daily email newsletter.